Prestige Consumer Healthcare (NYSE:PBH – Get Rating) had its target price cut by Oppenheimer to $63.00 in a research note published on Thursday, Stock Target Advisor reports.
Separately, DA Davidson reaffirmed a neutral rating on shares of Prestige Consumer Healthcare in a report on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $80.50.
Get
Prestige Consumer Healthcare alerts:
Prestige Consumer Healthcare Stock Up 0.4 %
PBH opened at $50.17 on Thursday. The company has a quick ratio of 1.23, a current ratio of 2.09 and a debt-to-equity ratio of 0.93. The firm has a 50 day moving average price of $54.61 and a 200-day moving average price of $55.26. Prestige Consumer Healthcare has a twelve month low of $48.51 and a twelve month high of $63.83. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of 12.57, a PEG ratio of 1.45 and a beta of 0.55.
Institutional Trading of Prestige Consumer Healthcare
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. M&G Investment Management Ltd. boosted its position in shares of Prestige Consumer Healthcare by 5.2% in the second quarter. M&G Investment Management Ltd. now owns 29,077 shares of the company's stock worth $1,716,000 after purchasing an additional 1,446 shares during the period. Summit Global Investments boosted its position in shares of Prestige Consumer Healthcare by 87.3% in the second quarter. Summit Global Investments now owns 48,428 shares of the company's stock worth $2,848,000 after purchasing an additional 22,566 shares during the period. Captrust Financial Advisors boosted its position in shares of Prestige Consumer Healthcare by 9.1% in the second quarter. Captrust Financial Advisors now owns 3,011 shares of the company's stock worth $177,000 after purchasing an additional 252 shares during the period. Legal & General Group Plc boosted its position in shares of Prestige Consumer Healthcare by 1.4% in the second quarter. Legal & General Group Plc now owns 144,276 shares of the company's stock worth $8,484,000 after purchasing an additional 1,926 shares during the period. Finally, Walleye Capital LLC boosted its position in shares of Prestige Consumer Healthcare by 255.2% in the second quarter. Walleye Capital LLC now owns 28,156 shares of the company's stock worth $1,656,000 after purchasing an additional 20,230 shares during the period. 99.37% of the stock is owned by hedge funds and other institutional investors.
About Prestige Consumer Healthcare
(Get Rating)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Recommended Stories
- Get a free copy of the StockNews.com research report on Prestige Consumer Healthcare (PBH)
- Humana Proves Vertically Integrated Healthcare Works
- This Small-Cap Healthcare Name Is Outperforming Its Index
- 2 Casino Stocks Worth Taking a Look At
- What Cintas Can Teach Investors About This Bear Market?
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
